Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Angiotensin II receptor antagonist plus a thiazide diuretic is more efficacious for treating hypertension than either drug alone
Autore:
McGill, JB;
Indirizzi:
Washington Univ, Sch Med, St Louis, MO 63110 USA Washington Univ St LouisMO USA 63110 iv, Sch Med, St Louis, MO 63110 USA
Titolo Testata:
BLOOD PRESSURE MONITORING
, volume: 6, anno: 2001, supplemento:, 1
pagine: S3 - S13
SICI:
1359-5237(200111)6:<S3:AIRAPA>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
LOW-DOSE HYDROCHLOROTHIAZIDE; TO-MODERATE HYPERTENSION; PLACEBO-CONTROLLED TRIAL; COMBINATION THERAPY; DOUBLE-BLIND; CIRCADIAN VARIATION; BLOOD-PRESSURE; TELMISARTAN; ENALAPRIL; MONOTHERAPY;
Keywords:
telmisartan; hydrochlorothiazide; hypertension; AT(1) receptor antagonist; combination therapy;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: McGill, JB Washington Univ, Sch Med, Campus Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA Washington Univ Campus Box 8127,660 S Euclid Ave St Louis MO USA 63110
Citazione:
J.B. McGill, "Angiotensin II receptor antagonist plus a thiazide diuretic is more efficacious for treating hypertension than either drug alone", BL PRESS M, 6, 2001, pp. S3-S13

Abstract

Objectives To identify a combination of telmisartan and hydrochlorothiazide (HCT) that provides anti hypertensive efficacy superior to that afforded by the individual monotherapies, and to characterize the dose-response profiles for telmisartan 20-160 mg and HCT 6.25-25 mg alone and in combination. Safety parameters, including serum electrolytes, were also assessed. Methods After a 4-week, single-blind, placebo run-in period, 818 patients aged 19-80 years with mild-to-moderate hypertension were allocated randomlyto groups to receive 8 weeks of double-blind, once-daily treatment with placebo, telmisartan (20, 40, 80, or 160 mg), HCT (6.25, 12.5, or 25 mg) or one of 12 telmisartan-HCT combinations. Results Telmisartan 80 mg + HCT 12.5 mg decreased mean supine systolic (SBP)/diastolic (DBP) trough blood pressures by 23.9/14.9 mmHg - a reduction 8.5/3.4 mmHg greater than that produced by telmisartan 80 mg and 17.0/7.6 mmHg greater than that produced by HCT 12.5 mg (P <0.01). Telmisartan 40 mg HCT 12.5 mg reduced mean supine SBP/DBP by 18.8/12.6 mmHg - an improvementof 6.6/1.9 mmHg over the reduction achieved with telmisartan 40 mg and of 11.9/5.3 mmHg over that achieved with HCT 12.5 mg (P < 0.01 for each comparison except that for the effect of telmisartan 40 mg on DBP). Response analyses confirmed the additive antihypertensive efficacy of telmisartan plus HCT All regimens were well tolerated. Telmisartan tended to ameliorate HCT induced serum potassium losses. Conclusions Telmisartan 80 mg + HCT 12.5 mg is an effective and well-tolerated treatment for patients with mild-to-moderate hypertension, providing significantly greater reductions in supine trough SBP and DBP than can be achieved with the individual monotherapies. (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/01/20 alle ore 19:07:10